

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

### Listing of claims:

Claims 1-10: (canceled)

Claim 11. (currently amended): A method of identifying evidence of a neoplasm in a biological sample comprising:

(a) examining a level of expression of 20P1F12/TMPRSS2 gene, which encodes the protein of SEQ. ID. NO: 2 (Figure 1), in a test biological sample; and

(b) comparing the level of said 20P1F12/TMPRSS2 gene expression in the test biological sample to a level of said 20P1F12/TMPRSS2 gene expression found in a comparable normal biological sample,

wherein an enhanced level of ~~said 20P1F12/TMPRSS2 gene products~~  
20P1F12/TMPRSS2 gene expression in the test biological sample relative to the normal biological sample is evidence of a neoplasm, and  
wherein the neoplasm is a prostate cancer.

Claim 12-18: (canceled)

Claim 19. (currently amended): A method of identifying evidence of a neoplasm in a biological sample comprising:

(a) examining a level of expression of 20P1F12/TMPRSS2 gene, which encodes the protein of SEQ. ID. NO: 2 (Figure 1), in a test biological sample; and

(b) comparing the level of said 20P1F12/TMPRSS2 gene expression in the test biological sample to a level of said 20P1F12/TMPRSS2 gene expression found in a comparable normal biological sample,

wherein an enhanced level of ~~said 20P1F12/TMPRSS2 gene products~~  
20P1F12/TMPRSS2 gene expression in the test biological sample relative to the normal  
biological sample is evidence of a neoplasm,

wherein the 20P1F12/TMPRSS2 evaluated in the test biological sample is secreted from  
neoplastic cells, and wherein the neoplastic cells are prostate cancer cells.

Claims 20-54. (canceled)

Claim 55. (currently amended): A method of identifying evidence of a neoplasm in a  
biological sample comprising:

(a) examining a level of expression of 20P1F12/TMPRSS2 gene, which encodes the  
protein encoded by a cDNA clone 20P1F12-GTC1 contained in the plasmid deposited with the  
American Type Culture Collection (ATCC) as Accession No. 207097, in a test biological  
sample; and

(b) comparing the level of said 20P1F12/TMPRSS2 gene expression in the test  
biological sample to a level of said 20P1F12/TMPRSS2 gene expression found in a comparable  
normal biological sample;

wherein an enhanced level of ~~said 20P1F12/TMPRSS2 gene products~~  
20P1F12/TMPRSS2 gene expression in the test biological sample relative to the normal  
biological sample is evidence of a neoplasm; and

wherein the neoplasm is a prostate cancer.

Claims 56-61. (canceled)

Claim 62. (previously presented): The method according to claim 11, wherein the  
level of 20P1F12/TMPRSS2 gene expression in the test biological sample is evaluated by  
examining the level of 20P1F12/TMPRSS2 protein.

Claim 63. (currently amended): The method of claim 62, wherein the level of  
20P1F12/TMPRSS2 protein is evaluated by an immunoassay by contacting the sample with an  
antibody or antibody fragment thereof which is immunoreactive with said protein and observing

the presence or absence of an immunocomplex formed from the antibody or fragment with ~~any~~ 20P1F12/TMPRSS2 protein.

Claim 64. (previously presented): The method according to claim 19, wherein the level of 20P1F12/TMPRSS2 gene expression in the test biological sample is evaluated by examining the level of 20P1F12/TMPRSS2 protein.

Claim 65. (currently amended): The method of claim 64, wherein the level of 20P1F12/TMPRSS2 protein is evaluated by an immunoassay by contacting the sample with an antibody or antibody fragment ~~thereof~~ which is immunoreactive with said protein and observing the presence or absence of an immunocomplex formed from the antibody or fragment with ~~any~~ 20P1F12/TMPRSS2 protein.

Claim 66. (previously presented): The method according to claim 55, wherein the level of 20P1F12/TMPRSS2 gene expression in the test biological sample is evaluated by examining the level of 20P1F12/TMPRSS2 protein.

Claim 67. (currently amended): The method of claim 66, wherein the level of 20P1F12/TMPRSS2 protein is evaluated by an immunoassay by contacting the sample with an antibody or antibody fragment ~~thereof~~ which is immunoreactive with said protein and observing the presence or absence of an immunocomplex formed from the antibody or fragment with ~~any~~ 20P1F12/TMPRSS2 protein.

Claim 68. (previously presented): The method of claim 55, wherein the 20P1F12/TMPRSS2 gene products evaluated in the test biological sample are secreted from neoplastic cells.